Involving Co-transfection Patents (Class 435/465)
-
Patent number: 11866494Abstract: The present disclosure relates to compositions and methods for enhancing CAR T therapy through uses of co-stimulation. Some embodiments relate to an isolated nucleic acid sequence encoding a chimeric antigen receptor (CAR) and an agent associated with a co-stimulatory molecule, the CAR comprising an intracellular domain of a costimulatory molecule.Type: GrantFiled: August 27, 2019Date of Patent: January 9, 2024Assignee: Innovative Cellular Therapeutics Holdings, Ltd.Inventors: Zhiyuan Cao, Chengfei Pu, Lei Xiao, Zhao Wu
-
Patent number: 11680254Abstract: The present invention encompasses engineered meganucleases which recognize and cleave a recognition sequence within the human PCSK9 gene. The present invention also encompasses methods for using such engineered meganucleases in a pharmaceutical composition and in methods for treating or reducing the symptoms of cholesterol-related disorders, such as hypercholesterolemia. Further, the invention encompasses pharmaceutical compositions comprising engineered meganuclease proteins, nucleic acids encoding engineered meganucleases, and the use of such compositions for treating cholesterol-related disorders, such as hypercholesterolemia.Type: GrantFiled: April 20, 2018Date of Patent: June 20, 2023Assignee: PRECISION BIOSCIENCES, INC.Inventors: Victor Bartsevich, Derek Jantz, James Jefferson Smith, Janel Lape
-
Patent number: 11364310Abstract: The present disclosure generally relates to viral-based expression systems suitable for the production of molecules of interest. The disclosure relates to nucleic acid constructs, such as expression vectors, containing a modified replicon RNA which includes a modified 5?-unstranslated region (5?-UTR) and, optionally, at least some of its original viral sequence encoding structural proteins having been deleted. Also disclosed are methods for producing polypeptides of interest.Type: GrantFiled: October 3, 2017Date of Patent: June 21, 2022Assignee: JANSSEN PHARMACEUTICALS, INC.Inventor: Kurt Iver Kamrud
-
Patent number: 9718871Abstract: Methods of generating sequence diversity in a protein, such as a ligand-binding protein, are provided. The methods comprise targeted introduction of two or more recombination signal sequences (RSSs) into the protein coding sequence and introduction of the modified protein coding sequence into a recombination-competent host cell, specifically a recombination-competent host cell that is capable of expressing at least RAG-1 and RAG-2, thereby allowing for recombination of the protein coding sequence and expression of variant proteins. Also provided are polynucleotides comprising a nucleic acid sequence encoding a target protein, such as a ligand-binding protein, and comprising two or more RSSs, and compositions and host cells comprising same.Type: GrantFiled: March 14, 2013Date of Patent: August 1, 2017Assignee: INNOVATIVE TARGETING SOLUTIONS INC.Inventors: Michael Gallo, Jaspal Singh Kang, Craig Robin Pigott, Abby Lin
-
Patent number: 9102943Abstract: The present invention provides a method for producing a virus vector, which comprises a step wherein cells that are capable of producing a virus vector are cultured in a culture medium that contains, as active components, a retinoic acid and a histone deacetylase inhibiting substance; and a culture medium for the production of a virus vector, which is characterized by containing, as active components, a retinoic acid and a histone deacetylase inhibiting substance.Type: GrantFiled: October 4, 2011Date of Patent: August 11, 2015Assignee: TAKARA BIO INC.Inventors: Kazuhisa Shinmura, Yoshinori Katayama, Kensuke Sakai, Toshihiro Shodai, Hirofumi Yoshioka, Junichi Mineno
-
Patent number: 9090673Abstract: Highly effective vaccine compositions are constructed according to the methods of this invention. The methods are amenable to use with any peptidic antigen sequence and involve covalent attachment of an immunostimulatory nucleotide sequence to an antigenic peptide sequence. Preferred antigenic peptides are fusion peptides made up of one or more CTL epitope peptides in sequence fused to a T helper peptide.Type: GrantFiled: December 13, 2004Date of Patent: July 28, 2015Assignee: CITY OF HOPEInventor: Don J. Diamond
-
Patent number: 9057056Abstract: The N-acetylglucosaminyltransferase III activity is enhanced in a cell carrying retrovirus-origin gag-pol gene and env gene. By constructing a retrovirus vector with the use of the above cell, a retrovirus vector having a modified sugar chain structure can be obtained. The retrovirus vector constructed by this method shows a high infection efficiency particularly in the presence of a functional substance.Type: GrantFiled: September 28, 2005Date of Patent: June 16, 2015Assignee: TAKARA BIO INC.Inventors: Hideto Chono, Hiromi Okuyama, Tomoe Egashira, Nobuto Koyama, Junichi Mineno, Ikunoshin Kato
-
Publication number: 20150150152Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to a novel ecdysone receptor/chimeric retinoid X receptor-based inducible gene expression system and methods of modulating gene expression in a host cell for applications such as gene therapy, large-scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.Type: ApplicationFiled: November 24, 2014Publication date: May 28, 2015Inventors: Marianna Zinovievna KAPITSKAYA, Subba Reddy Palli
-
Publication number: 20150118755Abstract: The disclosure relates to a method of reprogramming one or more somatic cells, e.g., partially differentiated or fully/terminally differentiated somatic cells, to a less differentiated state, e.g., a pluripotent or multipotent state. In further embodiments the invention also relates to reprogrammed somatic cells produced by methods of the invention, to uses of said cells, and to methods for identifying agents useful for reprogramming somatic cells.Type: ApplicationFiled: August 29, 2014Publication date: April 30, 2015Inventors: Rudolf Jaenisch, Yaqub Hanna, Marius Wernig, Christopher J. Lengner, Alexander Meissner, Oliver Tobias Brambrink, G. Grant Welstead, Ruth Foreman
-
Publication number: 20150079682Abstract: The invention includes compositions and methods for the selective expression of a target gene in a subset of cells. In certain embodiments, the present invention includes a construct comprising a first nucleic acid sequence comprising an episomal maintenance element and a second nucleic acid sequence comprising a target gene wherein the expression of the episomal maintenance element is regulated by a constitutive promoter and the expression of the target gene is regulated by a non-constitutive promoter. The construct is able to maintain episomal state, no matter whether the target gene is expressed in the cell.Type: ApplicationFiled: February 27, 2013Publication date: March 19, 2015Applicant: WAKE FOREST UNIVERSITY HEALTH SCIENCESInventors: Baisong Lu, Qingguo Zhao, James Yoo, Anthony Atala
-
Publication number: 20150072431Abstract: This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-?R) agonist and/or a tumor necrosis factor alpha receptor (TNF-?R) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7+ mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention. Such dendritic cells have enhanced immunostimulatory properties and increased IL-12 secretion and/or decreased IL-10 secretion. CD40 signaling can be initiated by one or more of polypeptide translated from an exogenous polynucleotide encoding CD40L (e.g.Type: ApplicationFiled: August 29, 2014Publication date: March 12, 2015Inventors: Don HEALEY, Irina Tcherepanova, Melissa Adams, Atsushi Hinohara
-
Patent number: 8936908Abstract: The present invention relates to a method for the production of a permanent human cell line, wherein isolated primary human cells are transfected simultaneously with a sequence allowing the expression of at least one cell transforming factor and a sequence allowing the expression of at least one recombinant polypeptide.Type: GrantFiled: March 7, 2006Date of Patent: January 20, 2015Assignee: CEVEC Pharmaceuticals GmbHInventors: Gudrun Schiedner, Christoph Volpers
-
Publication number: 20150011733Abstract: Disclosed are methods of making collagen 7, or functional fragments thereof, as well as collagen 7, and functional fragments thereof produced by such methods, nucleic acids encoding collagen 7, and functional fragments thereof, as well as vectors and host cells comprising such nucleic acids.Type: ApplicationFiled: August 3, 2012Publication date: January 8, 2015Inventors: Malini Viswanathan, Mark DeSouza
-
Publication number: 20140356960Abstract: The present invention relates to a nucleic acid containing at least one homing endonuclease site (HE) and at least one restriction enzyme site (X) wherein the HE and X sites are selected such that HE and X result in compatible cohesive ends when cut by the homing endonuclease and restriction enzyme, respectively, and the ligation product of HE and X cohesive ends can neither be cleaved by the homing endonuclease nor by the restriction enzyme. Further subject-matter of the present invention relates to a vector comprising the nucleic acid of the present invention, host cells containing the nucleic acid and/or the vector; a kit for cloning and/or expression of multiprotein complexes making use of the vector and the host cells, a method for producing a vector containing multiple expression cassettes, and a method for producing multiprotein complexes.Type: ApplicationFiled: April 25, 2014Publication date: December 4, 2014Inventor: Imre Berger
-
Publication number: 20140295489Abstract: The present invention relates to a novel selection system for use in a eukaryotic cell culture process and for expression of a recombinant product of interest. The selection system is based on the introduction of an exogenous functional membrane-bound folate receptor gene together with the polynucleotide or gene encoding the product of interest into a eukaryotic cell and can be widely utilized with eukaryotic cells for which cellular viability is dependent upon folic acid uptake.Type: ApplicationFiled: May 12, 2014Publication date: October 2, 2014Inventors: Yehuda G. Assaraf, Thomas Jostock, Hans-Peter Knopf
-
Publication number: 20140287511Abstract: Disclosed herein is the finding that Zscan4 is an early embryonic factor that facilitates cellular reprogramming. In particular, Zscan4 can replace the oncogenic reprogramming factor c-Myc to produce induced pluripotent stem cells when co-expressed with Klf4, Oct4 and Sox2. In addition, several Zscan4-dependent genes were identified that promote iPSC formation when co-expressed with known reprogramming factors. Thus, the present disclosure provides an ex vivo method of producing an iPS cell by reprogramming of a somatic cell. The method includes contacting the somatic cell with a Zscan4, or a Zscan4-dependent gene, and at least one reprogramming factor. Also provided are iPS cells produced by the disclosed method and non-human animals generated from such iPS cells.Type: ApplicationFiled: May 11, 2012Publication date: September 25, 2014Inventor: Minoru S.H. KO
-
Publication number: 20140273097Abstract: Disclosed herein are methods and compositions for inactivating a FUT8 gene, using fusion proteins comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding said fusion proteins are also provided, as are cells comprising said polynucleotides and fusion proteins.Type: ApplicationFiled: May 28, 2014Publication date: September 18, 2014Applicant: Sangamo BioSciences, Inc.Inventors: Trevor Collingwood, Gregory J. Cost
-
Patent number: 8822223Abstract: This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-?R) agonist and/or a tumor necrosis factor alpha receptor (TNF-?R) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7+ mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention. Such dendritic cells have enhanced immunostimulatory properties and increased IL-12 secretion and/or decreased IL-10 secretion. CD40 signaling can be initiated by one or more of polypeptide translated from an exogenous polynucleotide encoding CD40L (e.g.Type: GrantFiled: October 7, 2005Date of Patent: September 2, 2014Assignee: Argos Therapeutics, Inc.Inventors: Don Healey, Irina Tcherepanova, Melissa Adams
-
Publication number: 20140212922Abstract: Reverse engineering has offered new ways of studying the pathology of RNA viral infections, new more efficient devices of synthesizing recombinant viruses and developing vaccines and also demonstrated the versatility and efficiency of RNA dependent RNA polymerase RDRP system as an expression system. However, the currently used methods require a repertoire of complex, difficult-to-use tools. Present invention describes, a simpler plasmid based mammalian expression system that uses the RDRP enzyme activity for expression of recombinant proteins or RNA from viral minigenomes and rescue of recombinant viruses from cDNAs encoding entire genome(s) of negative stranded RNA viruses. This system will be useful for expression of recombinant proteins, therapeutic RNA molecules including anti-sense and/or selecting interfering RNA and Ribozymes. This system can also be used for gene therapy and producing recombinant viruses for production of new vaccines.Type: ApplicationFiled: June 8, 2012Publication date: July 31, 2014Inventor: Vishwas Joshi
-
Patent number: 8771983Abstract: A method is disclosed for releasing the transcriptional regulation caused by a repeated sequence in a gene, a kit therefor and so on to thereby establish a system capable of producing a protein in a large amount.Type: GrantFiled: August 14, 2007Date of Patent: July 8, 2014Assignee: National University of Corporation Hiroshima UniversityInventor: Noriaki Shimizu
-
Patent number: 8741340Abstract: The present invention relates to generation of cell lines expressing recombinant proteins for use in naked and encapsulated cell biodelivery of secreted therapeutic molecules. In one embodiment the cell line is human. In another aspect of the invention the transposon system is used for generating a cell line for secretion of a biologically active polypeptide.Type: GrantFiled: January 21, 2010Date of Patent: June 3, 2014Assignee: NsGene A/SInventors: Philip Kusk, Lars Ulrik Wahlberg
-
Patent number: 8734851Abstract: The present invention provides implantable medical devices coated with polyelectrolyte assemblies that are fabricated by layer-by-layer deposition of nucleic acid and polycation. Such devices facilitate the local delivery of a nucleic acid contained in the polyelectrolyte assembly into a cell or tissue at an implantation site. Also provided are methods of fabricating and using implantable medical devices according to the invention.Type: GrantFiled: May 1, 2006Date of Patent: May 27, 2014Assignee: Wisconsin Alumni Research FoundationInventors: David M. Lynn, Jingtao Zhang, Christopher M. Jewell, Nathaniel J. Fredin
-
Publication number: 20140140999Abstract: The invention provides means and methods for producing one or more Ig-like molecules in a single host cell. Novel CH3 mutations enabling the production of monospecific and/or bispecific Ig-like molecules of interest are also provided.Type: ApplicationFiled: November 15, 2013Publication date: May 22, 2014Applicant: MERUS B.V.Inventors: Cornelis A. DE KRUIF, Linda Johanna Aleida HENDRIKS, Ton LOGTENBERG
-
Patent number: 8716259Abstract: The present disclosure describes the broadly active chelation of diverse divalent 2+ metal cations by any oligonucleotide (ON), regardless of size or modification. This chelation effect is specific to cations which are divalent (or of higher valency) and results in the formation of oligonucleotide chelate complexes which do not behave like salts. It is described herein a novel composition of an ON chelate complex prepared using any ON and a divalent metal cation and methods for the suppression of anti-coagulation and or subcutaneous injection site reactions and or improved tolerability with oligonucleotides by the use of ON chelate complexes during oligonucleotide administration.Type: GrantFiled: May 30, 2013Date of Patent: May 6, 2014Assignee: Replicor Inc.Inventors: Andrew Vaillant, Michel Bazinet
-
Publication number: 20140093485Abstract: The application relates to a composition comprising: a stably integrating delivery vector; a modified mammalian thymidylate kinase (tmpk) wherein the modified mammalian tmpk increases phosphorylation of a prodrug relative to phosophorylation of the prodrug by wild-type human tmpk; and a detection cassette fused to tmpk. The application also relates to use of these compositions in methods of treatment of diseases such as graft versus host disease and cancer.Type: ApplicationFiled: September 26, 2013Publication date: April 3, 2014Applicant: University Health NetworkInventors: JEFFREY A. MEDIN, SEAN DEVINE
-
Publication number: 20140065178Abstract: The present invention provides pseudoinfectious alphavirus particles and methods of making them and using them to produce an immune response to an alphavirus in a subject.Type: ApplicationFiled: February 1, 2012Publication date: March 6, 2014Applicant: UAB RESEARCH FOUNDATIONInventors: Ilya Frolov, Elena Frolova
-
Patent number: 8637315Abstract: Processes vectors and engineered cell lines for large-scale transfection and protein production in mammalian cells, especially Chinese Hamster Ovary (CHO) cells are described in which transfection efficiencies are realized through the use of a single vector system, the use of functional oriP sequences in all plasmids, the use of codon-optimized Epstein-Barr virus nuclear antigen-1 (EBNA1) constructs the use of a fusion protein between a truncated Epstein-Barr virus nuclear antigenen-1c (EBNA1c) protein and a herpes simplex virus protein VP16, the use of a 40 kDa fully deacetylated poly(ethylenimine) as a transfection reagent, the use of co-expression of a fibroblast growth factor (FGF) and/or the use of protein kinase B to potentiate heterologous gene expression enhancement by valproic acid (VPA).Type: GrantFiled: March 9, 2009Date of Patent: January 28, 2014Assignee: National Research Council of CanadaInventors: Yves Durocher, Martin Loignon
-
Patent number: 8617533Abstract: Viral replicon selected nucleic acid expression libraries are useful for analyzing multiple antigens associated with a parasite, pathogen or neoplasia or for preparing immunogenic compositions for generating immune responses specific for the parasite, pathogen or neoplasia. Alphavirus replicon particles representative of the nucleic acid expression library are preferred. The nucleic acid library can be a random library, or it can be prepared after a selection step, for example, by differential hybridization prior to cloning into the replicon vector.Type: GrantFiled: May 6, 2008Date of Patent: December 31, 2013Assignee: AlphaVax, Inc.Inventors: Jonathan F. Smith, Kurt Kamrud, Sergey Dryga, Ian Caley
-
Publication number: 20130315872Abstract: The present invention provides a lentiviral vector system having a higher titer, while sustaining an excellent retrograde transport ability, particularly, in the brain. The present invention also provides a kit for preparing a retrograde transport viral vector comprising: (1) a packaging plasmid containing the gag gene and the pol gene of HIV-1; (2) a packaging plasmid containing an accessory gene of HIV-1; (3) a transfer plasmid containing an target gene (a transgene); and (4) an envelope plasmid containing, as an envelope gene, a gene encoding a fused polypeptide comprising a fused extracellular domain consisting of the N-terminal region of an extracellular domain of rabies virus glycoprotein (RV-G) and the C-terminal region of an extracellular domain of vesicular stomatitis virus glycoprotein (VSV-G), a transmembrane domain of RV-G or VSV-G, and an intracellular domain of VSV-G, and the like.Type: ApplicationFiled: November 25, 2011Publication date: November 28, 2013Applicant: JAPAN SCIENCE AND TECHNOLOGY AGENCYInventor: Kazuto Kobayashi
-
Patent number: 8592211Abstract: PiggyBac transposons and transposases with enhanced transposition activity in cells are provided. Also provided are associated methods and kits for both introducing exogenous DNA inserts into the genomes of host cells as well as for the removal of the inserts from the host cell genomes. Cells obtained by use of the compositions, methods and kits are also provided.Type: GrantFiled: March 22, 2010Date of Patent: November 26, 2013Assignee: The Rockefeller UniversityInventors: Ali Brivanlou, Arnaud Lacoste
-
Production of modified fatty acids in plants through rDNA targeted integration of heterologous genes
Patent number: 8546645Abstract: The present invention relates to transgenic plants comprising a plurality of nucleic acids heterologous to said plant, each of said nucleic acid comprising a coding sequence operably linked to one or more regulatory elements for directing expression of said coding sequence in said plant, said nucleic acid being stably integrated at or adjacent to rDNA sequences, or a seed, organ, tissue, part or cell thereof, or a descendant of said plant, seed, organ, tissue, part or cell; methods of producing the transgenic plants; and methods of producing oil using the transgenic plants.Type: GrantFiled: September 30, 2009Date of Patent: October 1, 2013Assignee: Agrisoma Biosciences Inc.Inventors: Steven Fabijanski, Michael Lindenbaum, Ping Fu, Elizabeth-France Marillia -
Patent number: 8524368Abstract: The present invention provides dynamic charge state cationic polymers that are useful for delivery of anionic molecules. The dynamic charge state cationic polymers are designed to have cationic charge densities that decrease by removal of removable functional groups from the polymers. The present invention also provides interpolyelectrolyte complexes containing the polymers complexed to a polyanion. Methods for using the interpolyelectrolyte complexes to deliver anionic compounds are also provided.Type: GrantFiled: December 14, 2011Date of Patent: September 3, 2013Assignee: Wisconsin Alumni Research FoundationInventors: David M. Lynn, Adam D. Miller
-
Patent number: 8513211Abstract: The present disclosure describes the broadly active chelation of diverse divalent 2+ metal cations by any oligonucleotide (ON), regardless of size or modification. This chelation effect is specific to cations which are divalent (or of higher valency) and results in the formation of oligonucleotide chelate complexes which do not behave like salts. It is described herein a novel composition of an ON chelate complex prepared using any ON and a divalent metal cation and methods for the suppression of anti-coagulation and or subcutaneous injection site reactions and or improved tolerability with oligonucleotides by the use of ON chelate complexes during oligonucleotide administration.Type: GrantFiled: August 18, 2011Date of Patent: August 20, 2013Assignee: Replicor Inc.Inventors: Andrew Vaillant, Michel Bazinet
-
Patent number: 8507269Abstract: Described herein are compositions and uses thereof related to Ca2+ release-activated Ca2+ (CRAC) channel activity. Also described herein CRAC channel modulators for treating diseases or conditions that would benefit from inhibition of SOC channel activity.Type: GrantFiled: May 27, 2008Date of Patent: August 13, 2013Assignee: CalciMedica, Inc.Inventors: Kenneth A. Stauderman, Jack Roos, Gonul Velicelebi
-
Patent number: 8486701Abstract: A method for modulating cell differentiation capabilities using heterologous gene expression. Some embodiments of the invention relate to a method for inducing a cardiac progenitor cell by delivering a reprogramming factor to the cell, wherein the reprogramming factor comprises ETS2 or a combination of ETS2 and Mesp1.Type: GrantFiled: March 4, 2011Date of Patent: July 16, 2013Assignees: University of Houston, Texas Heart Institute, The Texas A&M University SystemInventors: Robert J. Schwartz, Vladimir N. Potaman, Jose Francisco Islas
-
Publication number: 20130164851Abstract: Provided herein are methods and compositions for generating a cell line capable of producing a biological product, using a gene amplification based system. Methods and compositions are provided to inhibit endogenous selectable amplifiable marker genes using RNA interference and prevent the selection of false positives during generation of a custom cell line. Such methods improve efficiency of cell line development and do not require the use of specialized substrates or cells lacking the endogenous selectable amplifiable marker gene to negate the effect of endogenously expressed levels of the selectable amplifiable marker gene in cells.Type: ApplicationFiled: March 25, 2011Publication date: June 27, 2013Applicant: ALNYLAM PHARMACEUTICALS, INC.Inventors: Anthony Rossomando, Gregory P. Thill, Stuart Pollard
-
Publication number: 20130156736Abstract: A packaging cell line that complements recombinant adenoviruses based on serotypes from subgroup B, preferably adenovirus type 35. The cell line is preferably derived from primary, diploid human cells that are transformed by adenovirus E1 sequences either operatively linked on one DNA molecule or located on two separate DNA molecules, the sequences being operatively linked to regulatory sequences enabling transcription and translation of encoded proteins. Also disclosed is a cell line derived from PER.C6 that expresses functional Ad35 E1B sequences. The Ad35-E1B sequences are driven by the E1B promoter or a heterologous promoter and terminated by a heterologous poly-adenylation signal. The cell lines are useful for producing recombinant adenoviruses designed for gene therapy and vaccination. The cell lines can also be used for producing human recombinant therapeutic proteins such as human growth factors and human antibodies.Type: ApplicationFiled: March 27, 2012Publication date: June 20, 2013Inventors: Ronald VOGELS, Menzo Jans Emco Havenga, Majid Mehtall
-
Publication number: 20130143264Abstract: The present invention relates to purified and isolated DNA sequences having protein production increasing activity and more specifically to the use of matrix attachment regions (MARs) for increasing protein production activity in a eukaryotic cell. Also disclosed is a method for the identification of said active regions, in particular MAR nucleotide sequences, and the use of these characterized active MAR sequences in a new multiple transfection method.Type: ApplicationFiled: June 28, 2012Publication date: June 6, 2013Applicant: SELEXIS SAInventors: Mermod Nicolas, Pierre Alain Girod, Philipp Bucher, Duc-Quang Nguyen, David Calabrese, Damien Saugy, Stefania Puttini
-
Patent number: 8444965Abstract: The present invention relates to tumor cell-based vaccines and methods of using same, wherein the vaccines are based on naturally immune privileged tumor cells that have been genetically modified to express MHC-II restricted peptides derived from endogenously encoded tumor antigens, activate CD4+ T-lymphocytes, provide an array of antigens to which the host is not tolerized and/or induce immunity against the originating tumor cells as well as against metastatic tumor cells.Type: GrantFiled: September 23, 2010Date of Patent: May 21, 2013Assignee: University of Maryland, Baltimore CountyInventors: Suzanne Ostrand-Rosenberg, Jacobus J. Bosch, Bruce R. Ksander
-
Publication number: 20130065311Abstract: A method of producing an induced pluripotent stem cell includes introducing into a somatic cell one or more non-viral expression vectors. The vectors include one or more of an Oct family gene, a Klf family gene, a Sox family gene, a Myc family gene, a Lin family gene, and Nanog gene. The somatic cell is then cultured in a medium that supports pluripotent stem cells. At least a portion of the one or more introduced non-viral expression vectors is not substantially integrated in the chromosome.Type: ApplicationFiled: August 10, 2012Publication date: March 14, 2013Applicant: Kyoto UniversityInventors: Shinya Yamanaka, Keisuke Okita
-
Publication number: 20130052643Abstract: A method for generating a nuclear reprogrammed cell in accordance with the present invention includes the step of: introducing, into a somatic cell, (i) at least one gene selected from the group consisting of a gene encoding histone H2aa or a homologue thereof, a gene encoding histone H2ba or a homologue thereof, and a gene encoding a phosphorylation-mimic form of histone chaperon Npm2 or a phosphorylation-mimic form of a homologue of Npm2, and (ii) a nuclear reprogramming factor.Type: ApplicationFiled: August 29, 2012Publication date: February 28, 2013Applicant: RikenInventors: Shunsuke Ishii, Toshie Shinagawa
-
Publication number: 20130040302Abstract: Methods for producing engineered induced pluripotent stem (iPS) cells are provided comprising introducing a first nucleic acid into somatic cells for integration into their genome and reprogramming the cells to produce engineered iPS cells having the nucleic acid integrated into their genome. For example, in certain aspects the cells are reprogrammed by introduction of a genetic element that expresses one or more reprogramming factor and culturing of the cells under conditions sufficient to produce reprogrammed cells.Type: ApplicationFiled: July 11, 2012Publication date: February 14, 2013Inventors: Thomas J. Burke, Michael Miller, Michael McLachlan, Sarah Jane Dickerson, Anne Strouse
-
Publication number: 20130029423Abstract: Provided are a method of improving the efficiency of establishment of iPS cells, comprising the step of contacting one or more substances selected from the group consisting of members of the GLIS family (e.g., GLIS1) and nucleic acids that encode the same and one or more substances selected from the group consisting of members of the Klf family and nucleic acids that encode the same, with a somatic cell, an iPS cell comprising an exogenous nucleic acid that encodes a member of the GLIS family or a member of the Klf family, that can be obtained by the method, and a method of producing a somatic cell by inducing the differentiation of the iPS cell.Type: ApplicationFiled: February 16, 2011Publication date: January 31, 2013Applicants: Kyoto University, Japan Biological Informatics Consortium, National Institute of Advanced Industrial Science and TechnologyInventors: Shinya Yamanaka, Naoki Goshima, Momoko Maekawa, Yoshifumi Kawamura, Hiromi Mochizuki
-
Patent number: 8362324Abstract: Nucleic acid sequences and methods are provided for producing plants and seeds having altered tocopherol content and compositions. The methods find particular use in increasing the tocopherol levels in plants, and in providing desirable tocopherol compositions in a host plant cell.Type: GrantFiled: June 26, 2008Date of Patent: January 29, 2013Assignee: Monsanto Technology LLCInventors: Sai S. Subramaniam, Steven C. Slater, Katherine Karberg, Ridong Chen, Henry E. Valentin, Yun-Hua Huang Wong
-
Patent number: 8338180Abstract: The present invention provides methods of identifying an agent that inhibits an activity of a lentiviral Vif protein. The present invention provides methods of identifying an agent that increases the level of active APOBEC3G in a cell. The present invention provides agents identified by a subject screening method; and further provides methods for treating lentivirus infections.Type: GrantFiled: June 9, 2004Date of Patent: December 25, 2012Assignee: The J. David Gladstone InstitutesInventors: Warner C. Greene, Kimberly S. Stopak, Carlos M. C. deNoronha, Wesley M. Yonemoto
-
Publication number: 20120316066Abstract: The present invention provides diacylhydrazine ligands and chiral diacylhydrazine ligands for use with ecdysone receptor-based inducible gene expression systems. Thus, the present invention is useful for applications such as gene therapy, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable. An advantage of the present invention is that it provides a means to regulate gene expression and to tailor expression levels to suit the user's requirements.Type: ApplicationFiled: December 2, 2011Publication date: December 13, 2012Applicant: Intrexon CorporationInventors: Robert Eugene HORMANN, Bing Li
-
Publication number: 20120301438Abstract: The present invention is based on the seminal discovery that cord blood (CB) and adult bone marrow (BM) CD34+ cells can be reprogrammed to early stem cells. The invention provides the reprogramming of CB and adult bone marrow (BM) CD34+ cells from subjects without any pre-treatment. Provided are methods for reprogramming blood cells of a subject. Also provided are methods of disease modeling and methods of generating subject-specific differentiated cells. In addition, the invention provides methods of identifying an agent that alters a function of subject-specific differentiated cells as well as isolated pluripotent or multipotent stem cells reprogrammed from blood cells.Type: ApplicationFiled: September 14, 2010Publication date: November 29, 2012Applicant: THE JOHNS HOPKINS UNIVERSITYInventor: Linzhao Cheng
-
Publication number: 20120295964Abstract: Provided is a lentiviral vector system which sustains a high-frequency retrograde transportation ability in animal brain and has a higher titer. A kit for preparing a retrograde transport viral vector, which comprises: (1) a packaging plasmid containing the gag gene and pol gene of HIV-1; (2) a packaging plasmid containing an accessory gene of HIV-1; (3) a transfer plasmid containing a target gene; and (4) an envelope plasmid containing, as an envelope gene, a gene encoding a fused polypeptide comprising the extracellular domain of rabies virus glycoprotein (RV-G), the transmembrane domain of rabies virus glycoprotein (RV-G) or vesicular stomatitis virus glycoprotein (VSV-G) and the intracellular domain of vesicular stomatitis virus glycoprotein (VSV-G).Type: ApplicationFiled: November 11, 2010Publication date: November 22, 2012Applicant: JAPAN SCIENCE AND TECHNOLOGY AGENCYInventor: Kazuto Kobayashi
-
Publication number: 20120276579Abstract: The present invention relates to a novel selection system for use in a eukaryotic cell culture process and for expression of a recombinant product of interest. The selection system is based on the introduction of an exogenous functional membrane-bound folate receptor gene together with the polynucleotide or gene encoding the product of interest into a eukaryotic cell and can be widely utilized with eukaryotic cells for which cellular viability is dependent upon folic acid uptake.Type: ApplicationFiled: June 13, 2012Publication date: November 1, 2012Applicant: NOVARTIS AGInventors: Yehuda G. Assaraf, Thomas Jostock, Hans-Peter Knopf
-
Publication number: 20120270322Abstract: The present disclosure provides a DNA molecule capable of replication in Mycobacteria having a nucleic acid sequence as disclosed in SEQ ID NO: 1, a shuttle vector constructed using it and a transformed cells containing the present vector. The vector of about 18 kb of the present disclosure contains 16 ORFs, a replication origin and a rep-like protein essential for replication. Therefore, the plasmid of the present disclosure can be utilized as a gene delivery system/research, and also in a therapeutic system such as immune therapeutics by effectively delivering proteins or heterologous DNA and expressing the encoded DNA in cells.Type: ApplicationFiled: April 19, 2012Publication date: October 25, 2012Applicant: SNU R&DB FoundationInventors: Bum-Joon KIM, Hyungki LEE